IRLAB Therapeutics AB Class A (DE:6IRA)
FRANKFURT:6IRA
Want to see DE:6IRA full AI Analyst Report?
6IRA Stock Chart & Stats
€0.18
-€0.01(-1.25%)
At close: 4:00 PM EST
€0.18
-€0.01(-1.25%)
Day’s Range― - ―
52-Week Range€0.11 - €0.68
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.07M
Enterprise Value€83.39M
Total Cash (Recent Filing)€50.79M
Total Debt (Recent Filing)€27.08M
Price to Earnings (P/E)3.4
Beta-0.06
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding84,858,246
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.24
Revenue Forecast (FY)€8.91M
Bulls Say, Bears Say
Bulls Say
Revenue RecoverySustained, material revenue rebound (+60.9% TTM) indicates improving commercial or collaboration traction and stronger top-line momentum. Over 2-6 months this supports continued program funding, validates demand for assets, and improves prospects for partnerships or staged financing.
Manageable LeverageDebt/equity near 0.68 and improvement from 2024 signal a more manageable capital structure versus prior periods. This reduces immediate refinancing pressure, preserves optionality to raise debt or equity, and gives the company time to advance trials or secure partnerships.
Focused CNS PipelineA clear strategic focus on Parkinson’s and CNS disorders concentrates scientific expertise and trial design efforts. The specialization targets high unmet medical need and attractive partnering markets, increasing the odds of durable program progress and strategic collaborations.
Bears Say
High Cash BurnSustained ~-90M TTM operating and free cash flow creates chronic funding pressure. Over the medium term the company likely needs new capital to run trials, increasing dilution or debt risk and constraining ability to scale development without external partners or financings.
Persistent LossesNegative gross profit and ~-72% net margin reflect that core operations remain unprofitable. For a development-stage biotech this indicates ongoing subsidy by investors; absent clear near-term commercialization, losses will persist and weaken long-term return prospects.
Equity Erosion & Funding RelianceSubstantial equity erosion reduces financial flexibility and increases reliance on external financings. This elevates execution risk: adverse market conditions or higher capital costs could delay trials, force unfavorable deals, or dilute shareholders, impairing strategic optionality.
IRLAB Therapeutics AB Class A News
6IRA FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was €0.11 and its highest was €0.68 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is €10.07M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is Aug 26, 2026 which is in 96 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on May 06, 2026. The company reported €0.01 earnings per share for the quarter, beating the consensus estimate of N/A by €0.01.
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 84,858,246 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of €0.01 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -14.286%.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in DE:6IRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.
Technical Analysis
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
Initiator Pharma A/S
―